Travoprost and bimatoprost cause dry eye

Article

The use of travoprost 0.004% and bimatoprost 0.03% can have adverse effects on the ocular surface and can result in dry eye symptoms, according to Samet Ermis and co-workers from the Kocatepe University School of Medicine, Turkey.

The use of travoprost 0.004% and bimatoprost 0.03% can have adverse effects on the ocular surface and can result in dry eye symptoms, according to Samet Ermis and co-workers from the Kocatepe University School of Medicine, Turkey.

A total of 78 patients with primary open angle glaucoma (POAG) were enrolled; 44 patients received travoprost and 34 received bimatoprost. Complete ophthalmic examinations were performed before treatment and one week, one, three and six months after treatment. Intraocular pressure (IOP) was measured using Goldmann applanation tonometry and Schirmer and break-up time tests were performed during all examinations. Conjunctival cytology specimens were taken before and six-months after treatment and graded according to Nelson's classification and globlet cell density was evaluated.

In the travoprost group, mean IOP before treatment was 21.4±1.5 mmHg and 15.4±1.6 mmHg six months following treatment (p<0.05). In the bimatoprost group, mean IOP before treatment was 22.0±1.5 mmHg and 15.5 mmHg±1.4 mmHg six months after treatment (p<0.05). The authors found a statistically significant difference, between the two groups, in globlet cell density, Schirmer test and break-up time (p<0.05).

Although the decrease in IOP is statistically significant for both treatment groups, the study did show that travoprost and bimatoprost therapy can give rise to dry eye symptoms.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.